Novonesis has officially completed its acquisition of dsm-firmenich’s share in the Feed Enzyme Alliance, a strategic move that strengthens its position in the growing global market for animal nutrition and biosolutions. The acquisition, first announced in February, follows the satisfaction of all closing conditions and brings Novonesis another step closer to full vertical integration in the animal biosolutions space.
Strategic Expansion in Animal Nutrition
The acquisition enhances Novonesis’ ability to serve pork and livestock producers with a broader portfolio of enzyme and probiotic solutions. By incorporating dsm-firmenich’s sales and distribution activities into its already strong innovation and production pipeline, Novonesis will now operate as a fully integrated business across the entire value chain.
“With the closing of this strategic acquisition, we now have an expanded presence across the animal biosolutions value chain,” said Ester Baiget, CEO of Novonesis. “This positions us to create even more value for our customers with sustainable, value-adding solutions.”
The integration is already underway, with a focus on aligning sales, innovation, and operational capabilities to accelerate growth and expand customer reach.
Impact on Market and Performance
Although the acquisition won’t affect Novonesis’s organic sales growth, it is expected to boost reported sales performance in euros by approximately 1.5 percentage points. The company’s adjusted EBITDA margin outlook remains steady at 37–38%, with a €70 million contribution expected in the first full year.
-
Purchase price: €1.5 billion (all cash)
-
Revenue contribution: ~3% to group level; ~5% to Planetary Health division
-
EBITDA margin increase: ~0.5 percentage points for the group; ~1 percentage point for Planetary Health
-
EPS accretion: Low single-digit % in Year 1, mid single-digit % by Year 3
-
100% debt-financed, with strong expected cash flow to reduce leverage over two years
Novonesis will maintain its long-term supply relationship with dsm-firmenich for their premix business.
Why This Matters to Pork Producers
With the global feed enzyme market seeing rising demand, particularly in swine production, Novonesis is now positioned to deliver more comprehensive nutritional biosolutions that address:
-
Feed conversion efficiency
-
Gut health and immunity
-
Antibiotic-free production
-
Sustainability goals
As land constraints and environmental pressures mount, producers are seeking science-based solutions that deliver performance while meeting consumer and regulatory expectations. Novonesis’s expanded footprint ensures more integrated support for swine operations looking to optimize diets and reduce inputs.
—
Swine Web Takeaway:
Novonesis’s acquisition of dsm-firmenich’s share in the Feed Enzyme Alliance marks a major consolidation in the feed technology space—one that will benefit pork producers seeking cutting-edge, sustainable enzyme and probiotic solutions. As the biosolutions market continues to expand, this move reinforces Novonesis as a global leader in animal health innovation.
Stay tuned to Swine Web for ongoing updates on strategic moves shaping the future of animal nutrition.
